Treatment Options and Decisions
At a Glance
Treatment for sensorineural deafness with dilated cardiomyopathy combines individualized heart medicines and rhythm devices with hearing aids or cochlear implants. Regular heart and hearing checks help track changes, but treatment does not correct every genetic cause.
Managing a cardio-auditory phenotype requires a dual-track approach: supporting the heart’s pumping ability and maximizing your connection to the world through sound. While the genetic cause is the same, the treatments for your heart and ears are handled by different specialists working toward a common goal [1][2]. It is important to know that while these treatments can support function and improve your quality of life, they do not correct every underlying genetic cause.
Treatment Options and Decisions
Your care will follow a sequence: confirming the diagnosis, reviewing medicines and laboratory monitoring, repeating cardiac and hearing tests, assessing hearing-aid benefit, and deciding if a cochlear-implant evaluation is appropriate. You should also discuss exercise, salt/fluid advice, alcohol, work/driving, and pregnancy with your team.
Cardiac Care: Medication Management
For adults with symptomatic dilated cardiomyopathy (DCM) and a reduced ejection fraction (EF—a measure of how much blood the heart pumps out), modern medicine uses a combination of foundational drug classes. This is known as Guideline-Directed Medical Therapy (GDMT) [3][4].
- ARNI (Angiotensin Receptor-Neprilysin Inhibitor) or ACEi/ARB: These medications help relax blood vessels and reduce the workload on the heart. An ARNI is an alternative to an ACE inhibitor or ARB, not combined with them [3][5].
- Beta-blockers: These slow the heart rate and protect the heart muscle from stress hormones [6].
- MRA (Mineralocorticoid Receptor Antagonists): These help prevent scarring in the heart and manage fluid balance [3][7].
- SGLT2 Inhibitors: Originally for diabetes, these have been found to significantly reduce heart failure events and hospitalizations [8][9].
Current guidelines recommend starting these “four pillars” as soon as possible for appropriate adult patients [10][11]. However, these recommendations primarily describe selected patients with heart failure and reduced ejection fraction. Drug choice, age-specific dosing, and sequencing depend heavily on your EF, blood pressure, kidney function, potassium, congestion, age, pregnancy status, and whether the patient is a child. You must not start, stop, or demand these medications based on this guide without direct guidance from your treating clinician.
Device Therapy: ICDs and Pacemakers
If medications alone do not sufficiently improve heart function, your doctor may discuss an ICD (Implantable Cardioverter-Defibrillator). This device monitors your heart rhythm 24/7 and can deliver a life-saving shock if it detects a dangerous rhythm [12]. It does not strengthen the pump itself.
While an ejection fraction of 35% or less is a principal criteria for a primary-prevention ICD, it is not a stand-alone rule, and an EF just above or below 35% does not by itself determine treatment. Adult primary-prevention decisions consider symptoms, duration of optimized therapy, documented arrhythmias, expected survival, and selected genetic risks [12][13]. In some genetic forms, such as those involving the LMNA gene, an ICD might be considered even if the ejection fraction is higher [14][15]. Pediatric decisions differ significantly.
A pacemaker, conversely, is used when the heart’s “electrical wiring” is slow (AV block) [16].
Auditory Care: From Aids to Implants
Hearing loss in these conditions is often progressive, meaning it changes over time. Your audiology team will monitor your “aided thresholds”—how well you hear with your devices [2][17].
- Hearing Aids: For mild to moderate loss, high-quality digital hearing aids are the first line of defense. They are programmed to boost the specific frequencies (often mid-to-high) where you have the most trouble [18].
- Cochlear Implants (CI): If hearing aids no longer provide enough clarity to understand speech, a cochlear implant evaluation may be recommended. Unlike a hearing aid, a CI bypasses the damaged parts of the ear and stimulates the hearing nerve directly [19].
- Outcomes: Evidence shows that patients with syndromic hearing loss—including Alström and EYA4—can achieve excellent results with cochlear implants [20][21]. Early implantation is generally associated with better language outcomes [22][23]. However, a cochlear implant does not guarantee or restore normal hearing, and hearing in noise may remain difficult. Benefit varies widely with age, duration of deafness, aided speech understanding, cochlear-nerve status, and the particular syndrome.
Specialized Management Considerations
- Alström Syndrome: Care must go beyond the heart and ears to include regular screening for vision changes, diabetes, and kidney function [24][25].
- Mitochondrial Precautions: Risk during anesthesia depends on the exact disorder, heart function, and the surgical plan. Always provide the confirmed diagnosis and medication list to anesthesia, genetics, and cardiology to obtain a written, individualized perioperative plan before any procedure [26][21].
- Monitoring: Even if you feel well, annual “check-ups” for both systems (echocardiograms and audiograms) are the standard of care to catch subtle changes before they become emergencies [2][27].
Common questions in this guide
Which heart medicines may be used for dilated cardiomyopathy with reduced pumping function?
What determines whether I need an ICD or a pacemaker?
When should I consider a cochlear implant if hearing aids are not enough?
How often should my heart and hearing be checked?
What should I do before anesthesia or surgery?
Does Alström syndrome require monitoring beyond the heart and ears?
Get notified when new evidence is published on Sensorineural deafness with dilated cardiomyopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (27)
- 1
Genome-first approach to rare EYA4 variants and cardio-auditory phenotypes in adults.
Ahmadmehrabi S, Li B, Park J, et al.
Human genetics 2021; (140(6)):957-967 doi:10.1007/s00439-021-02263-6.
PMID: 33745059 - 2
Hearing Loss in Adults With Alström Syndrome-Experience From the UK National Alström Service.
Quoraishi S, Mason G, Geberhiwot T, Dalton CL
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2022; (43(6)):e620-e627 doi:10.1097/MAO.0000000000003553.
PMID: 35761454 - 3
Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction.
Ospina González OE, Llanos Mejía DC, Kaplinsky E, et al.
Drugs in context 2023; (12()) doi:10.7573/dic.2022-6-4.
PMID: 36660017 - 4
Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum.
Shahid I, Khan MS, Butler J, et al.
Heart failure reviews 2025; (30(3)):515-523 doi:10.1007/s10741-025-10481-7.
PMID: 39815071 - 5
Improving the Management of Patients with Heart Failure with Reduced Ejection Fraction in Clinical Practice: The Case for Angiotensin Receptor-Neprilysin Inhibitor.
Iacoviello M, Maria Sarullo F, Bilato C, et al.
Cardiac failure review 2025; (11()):e16 doi:10.15420/cfr.2024.39.
PMID: 40741340 - 6
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction.
Patel J, Rassekh N, Fonarow GC, et al.
Drugs 2023; (83(9)):747-759 doi:10.1007/s40265-023-01887-4.
PMID: 37254024 - 7
Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
Ferreira JP, Rossignol P, Machu JL, et al.
European journal of heart failure 2017; (19(10)):1284-1293 doi:10.1002/ejhf.900.
PMID: 28580625 - 8
Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study.
Svanström H, Mkoma GF, Hviid A, Pasternak B
The Lancet regional health. Europe 2026; (60()):101510 doi:10.1016/j.lanepe.2025.101510.
PMID: 41216476 - 9
How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure.
Newman E, Kamanu C, Gibson G, Brailovsky Y
Current cardiology reports 2024; (26(9)):995-1003 doi:10.1007/s11886-024-02101-x.
PMID: 39093374 - 10
Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J, Clephas PRD, Brunner-La Rocca HP, et al.
Heart failure reviews 2023; (28(5)):1221-1234 doi:10.1007/s10741-023-10325-2.
PMID: 37311917 - 11
Implementation of guideline-directed medical therapy for heart failure patients with reduced ejection fraction in Belgium: a Delphi panel approach.
Devoldere J, Droogmans S, Heggermont WA, Van Craenenbroeck E
Acta cardiologica 2024; (79(8)):897-908 doi:10.1080/00015385.2024.2396767.
PMID: 39254605 - 12
Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy.
Akhtar M, Elliott PM
Current cardiology reports 2019; (21(12)):155 doi:10.1007/s11886-019-1236-3.
PMID: 31768884 - 13
Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis.
Stolfo D, Albani S, Savarese G, et al.
International journal of cardiology 2020; (307()):75-81 doi:10.1016/j.ijcard.2020.02.025.
PMID: 32067834 - 14
Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals.
Kayvanpour E, Sedaghat-Hamedani F, Amr A, et al.
Clinical research in cardiology : official journal of the German Cardiac Society 2017; (106(2)):127-139 doi:10.1007/s00392-016-1033-6.
PMID: 27576561 - 15
Impact of genotype-phenotype associations on prognosis in dilated cardiomyopathy.
Stroeks SLVM, Wang P, Merlo M, et al.
European journal of heart failure 2025; (27(12)):3205-3218 doi:10.1002/ejhf.70040.
PMID: 40938777 - 16
Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.
Hasselberg NE, Haland TF, Saberniak J, et al.
European heart journal 2018; (39(10)):853-860 doi:10.1093/eurheartj/ehx596.
PMID: 29095976 - 17
Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients.
Lindsey S, Brewer C, Stakhovskaya O, et al.
American journal of medical genetics. Part A 2017; (173(8)):2210-2218 doi:10.1002/ajmg.a.38316.
PMID: 28573831 - 18
Hearing loss and cochlear implantation in Chudley McCullough syndrome: A case series.
Boerboom RA, Engels S, Ebbens FA, et al.
Cochlear implants international 2026; (27(1)):73-80 doi:10.1080/14670100.2025.2607227.
PMID: 41503747 - 19
Cochlear Implant Outcomes in Patients With TMTC2 -Associated Sensorineural Hearing Loss and Auditory Neuropathy/Auditory Dys-Synchrony.
North L, Olivier M, Runge CL
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2024; (45(6)):e478-e482 doi:10.1097/MAO.0000000000004208.
PMID: 38769084 - 20
Cochlear Implantation in Alport Syndrome: A Novel Case Series.
Moon E, Bond L, Gordon SA
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2026; (47(1)):e27-e30 doi:10.1097/MAO.0000000000004687.
PMID: 41170855 - 21
Cochlear Implants in Alström Syndrome.
Gheller F, Gallo S, Trevisi P, et al.
The Annals of otology, rhinology, and laryngology 2020; (129(8)):833-837 doi:10.1177/0003489420903061.
PMID: 32019320 - 22
Spoken Language Outcomes After Early Cochlear Implantation in a Diverse, Multi-Institutional Cohort of Congenitally Deaf Children.
Patel EJ, Stephans J, Yoon P, et al.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2026; (47(9)):1131-1136 doi:10.1097/MAO.0000000000004998.
PMID: 42417156 - 23
Pediatric cochlear implantation in residual hearing candidates.
Gratacap M, Thierry B, Rouillon I, et al.
The Annals of otology, rhinology, and laryngology 2015; (124(6)):443-51 doi:10.1177/0003489414566121.
PMID: 25586946 - 24
Consensus clinical management guidelines for Alström syndrome.
Tahani N, Maffei P, Dollfus H, et al.
Orphanet journal of rare diseases 2020; (15(1)):253 doi:10.1186/s13023-020-01468-8.
PMID: 32958032 - 25
Ocular evaluation and genetic test for an early Alström Syndrome diagnosis.
Etheridge T, Kellom ER, Sullivan R, et al.
American journal of ophthalmology case reports 2020; (20()):100873 doi:10.1016/j.ajoc.2020.100873.
PMID: 32944671 - 26
Spinal fusion with motor evoked potential monitoring using remimazolam in Alström syndrome: A case report.
Arashiro A, Shinzato H, Kamizato K, Kakinohana M
Medicine 2021; (100(47)):e27990 doi:10.1097/MD.0000000000027990.
PMID: 34964794 - 27
Familial dilated cardiomyopathy: A multidisciplinary entity, from basic screening to novel circulating biomarkers.
de Gonzalo-Calvo D, Quezada M, Campuzano O, et al.
International journal of cardiology 2017; (228()):870-880 doi:10.1016/j.ijcard.2016.11.045.
PMID: 27889554
This page explains treatment choices for sensorineural deafness with dilated cardiomyopathy for informational purposes only and does not constitute medical advice. Medication, device, anesthesia, and cochlear-implant decisions should be individualized with your treating clinicians.